FibroGen Rebrands as Kyntra Bio, Advances CD46-Targeting ADC and Roxadustat Programs
Key Insights
FibroGen has rebranded to Kyntra Bio (search), reflecting its strategic focus on oncology and rare disease therapeutics with a strengthened financial position extending cash runway into 2028.
The company is advancing FG-3246, a first-in-class CD46 (search)-targeting antibody-drug conjugate in Phase 2 trials for metastatic castration-resistant prostate cancer (search), with topline combination results expected at ASCO GU 2026.
Roxadustat received FDA Orphan Drug Designation for myelodysplastic syndromes (search), with a pivotal Phase 3 trial protocol submitted for treating anemia (search) in lower-risk MDS patients.
FibroGen announced its rebranding to Kyntra Bio (search) on January 7, 2026, marking a strategic transformation focused on oncology and rare disease therapeutics. The company will begin trading on Nasdaq under the new symbol "KYNB" effective January 8, 2026, following a transformational 2025 that included the sale of FibroGen China and payoff of senior secured debt.
"2025 was a transformational year, highlighted by the sale of FibroGen China, the payoff of our senior secured term loan, and the extension of our cash runway into 2028," said Thane Wettig, Chief Executive Officer of Kyntra Bio (search). "Today, with a sharpened direction, Kyntra Bio is laser-focused on our mid- and late-stage assets."
CD46-Targeting Platform Shows Promise in Prostate Cancer
Kyntra Bio (search)'s lead oncology program centers on FG-3246, a first-in-class antibody-drug conjugate targeting CD46 (search), currently in Phase 2 development for metastatic castration-resistant prostate cancer (search) (mCRPC). The company expects to present topline results from an investigator-sponsored Phase 1b/2 study conducted by UCSF, evaluating FG-3246 in combination with enzalutamide in mCRPC patients, at ASCO GU in the first quarter of 2026.
The program includes FG-3180, a companion CD46 (search)-targeted PET imaging agent designed to assess diagnostic performance and determine potential correlation between CD46 expression and response to FG-3246. Interim results from the recently commenced Phase 2 monotherapy trial are expected in the second half of 2026, with the trial also evaluating FG-3180's diagnostic capabilities.
Roxadustat Advances in Rare Disease
The company's roxadustat program received significant regulatory support with FDA Orphan Drug Designation for the treatment of myelodysplastic syndromes (search) (MDS). Kyntra Bio (search) has submitted the pivotal Phase 3 clinical trial protocol for roxadustat for treating anemia (search) in patients with lower-risk MDS and high transfusion burden to the FDA.
Roxadustat is currently approved in Europe, Japan, and numerous other countries for treating anemia (search) in chronic kidney disease (search) patients on dialysis and not on dialysis. The company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome in the U.S.
Strategic Focus and Financial Position
The rebranding reflects Kyntra Bio (search)'s evolution into a company focused on creating "outsized impact for patients and shareholders," according to Wettig. The company's strengthened financial position, with cash runway extended into 2028, provides a foundation for advancing its clinical programs.
Kyntra Bio (search) is refreshing its corporate website to better reflect the company's strategy moving forward, while the CUSIP number for the company's common stock remains unchanged. The transformation positions the company to focus on its mid- and late-stage assets with potential for significant clinical impact in oncology and rare disease.